These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 38481800)

  • 1. Impact of KRAS mutation on the tumor microenvironment in colorectal cancer.
    Zhou Y; Kuang Y; Wang C; Yu Y; Pan L; Hu X
    Int J Biol Sci; 2024; 20(5):1947-1964. PubMed ID: 38481800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of RAS mutations on the immune infiltrate of colorectal liver metastases: A preliminary study.
    Polidoro MA; Milana F; Soldani C; Franceschini B; Anselmo A; Colombo FS; Di Tommaso L; Cimino M; Carnevale S; Lleo A; Jaillon S; Torzilli G; Donadon M
    J Leukoc Biol; 2020 Aug; 108(2):715-721. PubMed ID: 32108374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy.
    Wang G; Wang JJ; Yin PH; Xu K; Wang YZ; Shi F; Gao J; Fu XL
    J Cell Physiol; 2019 May; 234(5):5601-5612. PubMed ID: 30341899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The current understanding on the impact of KRAS on colorectal cancer.
    Meng M; Zhong K; Jiang T; Liu Z; Kwan HY; Su T
    Biomed Pharmacother; 2021 Aug; 140():111717. PubMed ID: 34044280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status.
    Lee J; Jain A; Kim P; Lee T; Kuller A; Princen F; In-GuDo ; Kim SH; Park JO; Park YS; Singh S; Kim HC
    PLoS One; 2014; 9(8):e103551. PubMed ID: 25090459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant RAS and BRAF mutation in colorectal cancer - A report of 7 cases.
    Ates O; Yalcin S
    Indian J Cancer; 2019; 56(2):176-179. PubMed ID: 31062740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One Mutation to Rule Them All: Mutant KRAS Controls Tumor Intrinsic and Microenvironment Signaling.
    Müller S; Krishnamurty AT
    Cancer Res; 2024 Jan; 84(1):6-8. PubMed ID: 38016110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis.
    Jackstadt R; van Hooff SR; Leach JD; Cortes-Lavaud X; Lohuis JO; Ridgway RA; Wouters VM; Roper J; Kendall TJ; Roxburgh CS; Horgan PG; Nixon C; Nourse C; Gunzer M; Clark W; Hedley A; Yilmaz OH; Rashid M; Bailey P; Biankin AV; Campbell AD; Adams DJ; Barry ST; Steele CW; Medema JP; Sansom OJ
    Cancer Cell; 2019 Sep; 36(3):319-336.e7. PubMed ID: 31526760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colorectal cancer-derived exosomes and modulation KRAS signaling.
    Wan YH; Liu QS; Wan SS; Wang RW
    Clin Transl Oncol; 2022 Nov; 24(11):2074-2080. PubMed ID: 35789981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA‑337 inhibits colorectal cancer progression by directly targeting KRAS and suppressing the AKT and ERK pathways.
    Liu X; Wang Y; Zhao J
    Oncol Rep; 2017 Nov; 38(5):3187-3196. PubMed ID: 29048669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unveiling the role of KRAS in tumor immune microenvironment.
    Xu M; Zhao X; Wen T; Qu X
    Biomed Pharmacother; 2024 Feb; 171():116058. PubMed ID: 38171240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS as a Modulator of the Inflammatory Tumor Microenvironment: Therapeutic Implications.
    Pereira F; Ferreira A; Reis CA; Sousa MJ; Oliveira MJ; Preto A
    Cells; 2022 Jan; 11(3):. PubMed ID: 35159208
    [No Abstract]   [Full Text] [Related]  

  • 14. The potential of PIK3CA, KRAS, BRAF, and APC hotspot mutations as a non-invasive detection method for colorectal cancer.
    Alizadeh-Sedigh M; Mahmoodzadeh H; Fazeli MS; Haddadi-Aghdam M; Teimoori-Toolabi L
    Mol Cell Probes; 2022 Jun; 63():101807. PubMed ID: 35296442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long noncoding RNA SNHG14 accelerates cell proliferation, migration, invasion and suppresses apoptosis in colorectal cancer cells by targeting miR-944/KRAS axis through PI3K/AKT pathway.
    Pei Q; Liu GS; Li HP; Zhang Y; Xu XC; Gao H; Zhang W; Li T
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9871-9881. PubMed ID: 31799655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer.
    Bahrami A; Hassanian SM; ShahidSales S; Farjami Z; Hasanzadeh M; Anvari K; Aledavood A; Maftouh M; Ferns GA; Khazaei M; Avan A
    J Cell Physiol; 2018 Mar; 233(3):2058-2066. PubMed ID: 28262927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
    Wang Z; Kang B; Gao Q; Huang L; Di J; Fan Y; Yu J; Jiang B; Gao F; Wang D; Sun H; Gu Y; Li J; Su X
    Cancer Sci; 2021 Sep; 112(9):3895-3910. PubMed ID: 34185934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer.
    Zhu G; Pei L; Xia H; Tang Q; Bi F
    Mol Cancer; 2021 Nov; 20(1):143. PubMed ID: 34742312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAS mutation: site of disease and recurrence pattern in colorectal cancer.
    Bonnot PE; Passot G
    Chin Clin Oncol; 2019 Oct; 8(5):55. PubMed ID: 31597436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS inhibition in metastatic colorectal cancer: An update.
    Nusrat M; Yaeger R
    Curr Opin Pharmacol; 2023 Feb; 68():102343. PubMed ID: 36638742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.